Depots and encasement structures for implantable devices
Encasement structures and methods of customizing patient drug delivery profiles using an encasement structure are described herein. Encasement structures can be configured to receive an implantable medical device and physicians can implant the medical devices within the encasement structures. Encasement structures can include at least one sheet of a bioscaffold material and one or more depots. Depots can be configured to release an active agent, such as an antibiotic, to the medical device within the encasement structure and/or the surrounding tissue. The depots can be insertable into or integrated with the at least one sheet of bioscaffold material.
1 . An encasement structure comprising:
at least one sheet comprising a bioscaffold material, the at least one sheet configured to define an internal region that is sized and shaped to hold an implantable medical device therein;
one or more ring-shaped depots associated with the at least one sheet, and
one or more pockets positioned on a surface of the encasement structure or within an internal region of the encasement structure configured to receive and secure the one or more ring-shaped depots,
wherein the one or more ring-shaped depots comprise an effective therapeutic amount of one or more active agents and a bioabsorbable material, and are configured to release the one or more active agents over a period of time.
2 . The encasement structure of claim 1 , wherein the bioscaffold material comprises decellularized extracellular matrix (ECM).
3 . The encasement structure of claim 2 , wherein the decellularized extracellular matrix is acellular.
4 . The encasement structure according to claim 2 , wherein the ECM is derived from mammalian tissue.
5 . The encasement structure according to claim 2 , wherein the ECM is derived from one or more of small intestine submucosa (SIS); urinary bladder submucosa (UBS); stomach submucosa (SS); central nervous system tissue; other tissue of mesodermal origin; dermal tissue; subcutaneous tissue; gastrointestinal tissue; tissue surrounding growing bone; placental tissue; omentum tissue; cardiac tissue; kidney tissue; pancreatic tissue; lung tissue; and any combination thereof.
6 . The encasement structure according to claim 1 , wherein the bioscaffold material comprises small intestine submucosa.
7 . The encasement structure according to claim 1 , wherein the one or more ring-shaped depots comprises one or more of a bioabsorbable polymer or a hydrogel.
8 . The encasement structure according to claim 1 , wherein the one or more ring-shaped depots comprises a copolymer of lactic acid and glycolic acid.
9 . The encasement structure according to claim 1 , wherein the period of time is about 1 week to about 3 months.
10 . The encasement structure according to claim 1 , wherein the at least one sheet comprises two or more laminae of the bioscaffold material.
11 . The encasement structure according to claim 1 , wherein the at least one sheet comprises four laminae of the bioscaffold material.
12 . The encasement structure according to claim 1 , wherein the at least one sheet comprises two laminae of the bioscaffold material, and wherein the encasement structure is configured to receive and secure the one or more ring-shaped depots between the two laminae of the bioscaffold material.
13 . The encasement structure according to claim 1 , wherein the one or more active agents are selected from the group consisting of antibiotics, antifungal agents, anti-viral agents, anti-pain agents, anesthetics, analgesics, steroidal anti-inflammatories, non-steroidal anti-inflammatories, anti-neoplastics, anti-spasmodics, hormones, enzymes, enzyme inhibitors, anticoagulants, antithrombic agents, polypeptides, oligonucleotides, polynucleotides, nucleoproteins, compounds modulating cell migration, compounds modulating proliferation of tissue, compounds modulating growth of tissue, vasodilating agents, anti-hematoma agents, anti-scarring agents, and combinations thereof.
14 . The encasement structure according to claim 1 , wherein the one or more active agents comprise one or more antibiotics.
15 . The encasement structure according to claim 14 , wherein the one or more antibiotics comprise rifampin and minocycline.
16 . The encasement structure according to claim 1 , wherein the one or more ring-shaped depots in combination comprise about 5 mg to about 20 mg of the one or more active agents.
17 . The encasement structure according to claim 1 , wherein the one or more ring-shaped depots comprise a first ring-shaped depot exhibiting a first active agent release period and a second ring-shaped depot exhibiting a second active agent release period, wherein the first active agent release period and the second active agent release period are different.
18 . A kit comprising:
one or more encasement structures, each encasement structure comprising:
at least one sheet comprising a bioscaffold material, the at least one sheet configured to define an internal region that is sized and shaped to hold an implantable medical device therein; and
one or more ring-shaped depots comprising one or more active agents and a bioabsorbable material, wherein the one or more ring-shaped depots are configured to release the one or more active agents over a period of time, and
one or more pockets positioned on a surface of the encasement structure or within an internal region of the encasement structure configured to receive and secure the one or more ring-shaped depots.
19 . A method of reducing a risk of an adverse effect associated with implanting a medical device in a subject in need thereof, the method comprising:
inserting the medical device into an encasement structure to form an encased medical device, the encasement structure comprising:
at least one sheet comprising a bioscaffold material, the at least one sheet configured to define an internal region that is sized and shaped to hold the medical device therein;
one or more ring-shaped depots associated with the at least one sheet, and
one or more pockets positioned on a surface of the encasement structure or within an internal region of the encasement structure configured to receive and secure the one or more ring-shaped depots,
wherein the one or more ring-shaped depots comprise an effective therapeutic amount of one or more active agents and a bioabsorbable material, and are configured to release the one or more active agents over a period of time;
and
implanting the encased medical device into the subject.